SKIN CANCER

Skin cancer in organ transplant recipients

The high risk of skin cancer after organ transplantation is a major clinical challenge. Taking advantage of a high-quality national cancer registry, we have studied long-term changes in the risk of cutaneous squamous cell carcinoma after organ transplantation in Norway.

PhD project: Syed Mohammad Husain Rizvi. Main supervisor: Petter Gjersvik.

 

Fractional laser-assisted daylight photodynamic therapy for multiple actinic keratoses of the scalp in organ transplant recipients: a randomized half-side comparative trial

Organ transplant recipients (OTRs) are at high risk of skin cancer, especially squamous cell carcinoma (SCC). SCC often develops in the area of field cancerization, areas exposed for chronical sun damage and multiple actinic keratoses (AK). It is of high clinical value to treat precancerous lesions such as AK among OTRs. In order to evaluate more effective treatment of AKs/field cancerization in OTRs we set out a randomized half-side comparative trial to investigate the effect of pre-treating the skin with ablative, fractional carbon dioxide laser before daylight PDT.

Project leader: Syed Mohammad Husain Rizvi. Others: Gro Mørk, Petter Gjersvik, Per Helsing.

 

Folliculotropic mycosis fungoides

Folliculotropic mycosis fungoides (FMF) is a variant of mycosis fungoides (MF) with distinct clinical and histopathological features. Folliculotropism may suggest that antigen-stimulation by particular antigens present in the hair follicle contribute to the pathogenesis.

PhD project: Patty Mantaka. Main supervisor: Jan Delabie. Co-supervisor: Petter Gjersvik. Collaborator: Department of Pathology, OUS Radiumhospitalet.

 

Validation of staging systems for cutaneous squamous cell carcinoma: a population-based, nested case-control study

In this study, we aim to determine the rate of metastasis in cutaneous squamous cell carcinoma (cSCC) in Norway, by using high-quality population-based data.  Also, we aim to assess the impact of reported risk factors for metastasis and to externally validate three existing current cSCC staging systems for their reproducibility and practicality.

Project leader: Ingrid Roscher. Others: Petter Gjersvik, Per Helsing. Collaborators: Department of Pathology, Oslo University Hospital, Oslo, Norway; Cancer Registry of Norway; Oslo Centre for biostatistics and epidemiology, Oslo University Hospital, Oslo, Norway